WAVE LIFE SCIENCES LTD. Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
WAVE LIFE SCIENCES LTD. (WVE) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $575.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-23.
Discontinued › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2023-03-23
- WAVE LIFE SCIENCES LTD. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2021 was $575.00K, a 83.71% increase from fiscal 2020.
- WAVE LIFE SCIENCES LTD. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2020 was $313.00K, a 1260.87% increase from fiscal 2019.
- WAVE LIFE SCIENCES LTD. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2019 was $23.00K.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month |
|---|---|
| 2021-12-31 | $575.00K 10-K · filed 2023-03-23 |
| 2020-12-31 | $313.00K 10-K · filed 2022-03-03 |
| 2019-12-31 | $23.00K 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |